Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30 2018 - 8:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage
biopharmaceutical company developing innovative, targeted
therapeutics for the treatment of cancer, today announced that
Peter D. Suzdak, Ph.D., the Company's chief executive officer, will
present a corporate overview at the 20th Annual Rodman &
Renshaw Global Investment Conference sponsored by H.C. Wainwright
& Co., LLC. The conference is being held on September 4-6, 2018
in New York City.
Presentation Details:
Date: |
Thursday, September 6 |
Time: |
9:35 am Eastern Time |
Location: |
The St. Regis New York, in
Library (2nd floor) |
Webcast: |
A live audio webcast of
the presentation will be available and can be accessed through the
following hyperlink http://wsw.com/webcast/rrshq28/rnn/, or from
the Company's website, under the "Investor Relations - Events and
Presentations" section. |
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical
stage biopharmaceutical company dedicated to developing novel,
targeted therapeutics for the treatment of cancer. The company's
mission is to improve the lives of cancer patients by developing
next-generation cancer therapies that are designed to maximize
efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn's product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that certain
of Rexahn's product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers, and others may augment the
effectiveness of current FDA-approved cancer treatments. The
company has two oncology product candidates, RX-3117 and RX-5902,
in Phase 2 clinical development and additional compounds in
preclinical development including RX-0201. For more information
about the Company and its oncology programs, please
visit www.rexahn.com.
Media Contact:DGI CommSusan Forman or Laura
Radocaj
+1-212-825-3210sforman@dgicomm.com lradocaj@dgicomm.com
Investor contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024